Takeda Pharmaceutical Company Limited (NYSE:TAK) saw a downside of -0.37% to close Tuesday at $16.13 after subtracting -$0.06 on the day. The 5-day average trading volume is 2,816,020 shares of the company’s common stock. It has gained $16.30 in the past week and touched a new high 3 times within the past 5 days. An average of 3,176,165 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,856,574.
TAK’s 1-month performance is 4.74% or $0.59 on its low of $15.27 reached on 01/10/23. The company’s shares have touched a 52-week low of $12.28 and high of $16.30, with the stock’s rally to the 52-week high happening on 01/20/23. YTD, TAK has achieved 3.40% or $0.53 and has reached a new high 6 times. However, the current price is down -1.04% from the 52-week high price.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
TAK stock has a beta of 0.68. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.73 while the price-to-book (PB) in the most recent quarter is 0.96, with the price to cash flow ratio at 10.59.
Takeda Pharmaceutical Company Limited’s quick ratio for the recent period was 0.70, with the current ratio over the same period at 1.10.. In terms of profitability, the gross margin trailing 12 months is 68.30%. The trailing 12-month EBITDA margin is 33.44%. The firm’s gross profit as reported stood at $21.91 billion against revenue of $31.76 billion.
Takeda Pharmaceutical Company Limited’s cash and short-term investments amounted to $266.65 million against total debt of $5.11 trillion. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -100.94% to $1.69 billion, while revenue of $0.0 was 100.0% off the previous quarter. EBITDA for the quarter stood at more than $1.88 billion. TAK stock balance sheet for the recent quarter shows that total liabilities totaled 56.7 billion, with total debt at $5.11 trillion.
Let’s look briefly at Takeda Pharmaceutical Company Limited (TAK) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 65.92% to suggest the stock is trending Neutral, with historical volatility in this time period at 12.21%.
The stock’s 5-day moving average is $16.19, reflecting a -0.12% or -$0.02 change from its current price. TAK is currently trading +4.60% above its 20-day SMA, +16.71% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +22.01% and SMA200 by+9.95%.
Stochastic %K and %D was 89.92% and 91.68% and the average true range (ATR) pointed at 0.21. The RSI (14) points at 66.74%, while the 14-day stochastic is at 83.41% with the period’s ATR at 0.21. The stock’s 9-day MACD Oscillator is pointing at 0.14 and 0.33 on the 14-day charts.
In the most recent analyst report for Takeda Pharmaceutical Company Limited (NYSE: TAK), Cowen upgraded it to an Outperform rating. They previously had a Market perform rating on the stock. Analysts offering their rating for TAK stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate TAK as a “sell,”, while 7 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 1 rates the stock as overweight while 5 have offered a “buy” rating.
What is TAK’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $13.56 and a high of $25.52, with their median price target at $16.32. Looking at these predictions, the average price target given by analysts is for Takeda Pharmaceutical Company Limited (TAK) stock is $17.14.